Pharmaceutical companies are unable to challenge the introduction of new rules of pricing of drugs in Canada

The Federal court of Canada rejected the claim of the pharmaceutical manufacturers the government, have adopted new legislation to reduce the cost of patented medicines. As stated by the manufacturers, they can lose billions of dollars in profits for a decade, reports Reuters.

Canada first published the new rules in August 2019. Innovation should become a major reform of the pricing system for pharmaceuticals since 1987. Under the new rules, Expert advice on the approval of prices of original drugs will change the list of reference countries used for comparison of the cost of drugs. So, the list will be excluded the US and Switzerland as the country with the highest drug prices, and therefore not suitable for evaluating the economic efficiency.

Dissatisfied with the innovations were a number of the world’s largest pharmaceutical manufacturers. A joint suit against the government amounted to Pfizer Inc., AbbVie Corp, Amgen Inc, Bristol Myers Squibb Co, AstraZeneca Plc, Novartis AG and Eli Lilly.

The new rules were to take effect from 1 July, however, the period of their introduction was postponed to January 1, 2021.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]